PCM - Patient-Derived Xenograft Repository
Patient derived xenografts (PDX) are samples grafted directly from a patient into an immunodeficient mouse. Under these conditions, the tumor continues to grow and metastasize, allowing propagation of the human cancer.
The Precision Cancer Models (PCM) maintains and distributes viable crypopreserved tumor tissue, organoids, and unstained FFPE tumor sections associated with all common subtypes of breast cancer. Publications have shown that the breast PDX models maintain similar molecular profiles to the parent tumor, meaning these tumor grafts create an excellent model to test new chemotherapies and drug delivery systems in a preclinical setting.
We can help you use these tumor models to test your small molecule, including implantation of tumor tissue, tumor growth monitoring, drug dosing, and necropsy.
For more information on these models, please see these publications:
- A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology
- Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
- Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine
Model Access & Pricing
The Precision Cancer Models (PCM) Shared Resource provides access to a diverse repository of sophisticated cancer models, including patient-derived xenografts (PDX) and patient-derived organoids (PDO). These models support translational cancer research and are available to both internal and external academic investigators.
In addition to distributing models, PCM also performs PDX and PDO studies upon request, including tumor implantation, treatment evaluation, imaging, and tissue analysis. Our experienced team can work with investigators to design and execute preclinical studies tailored to specific research questions.
Pricing Information
Please email Dr. David Lum for current rates and service details. Pricing may vary depending on project scope and institutional affiliation.
Biotech & Pharmaceutical Companies
For-profit entities must coordinate through the University of Utah’s Technology Licensing Office (TLO) to establish appropriate licensing agreements and discuss any applicable royalties. Dr. Lum can help facilitate these connections upon request.
In addition to the characterized breast PDX model, we work closely with the BMP to collect and transplant other cancer types, including melanoma. If there is a specific cancer you would like collected, we can work to facilitate your requests.
For further inquiries, please contact us.
Contact Us
Email: prr@hci.utah.edu